Drug-resistant cytomegalovirus in transplant recipients: a French cohort study.

Sébastien Hantz 1, 2 Françoise Garnier-Geoffroy 2 Marie-Christine Mazeron 3 Isabelle Garrigue 4 Pierre Merville 5 Catherine Mengelle 6 Lionel Rostaing 7 Franck Saint-Marcoux 8 Marie Essig 9 Jean-Philippe Rerolle 9 Sébastien Cotin 1 Raphaëlle Germi 10 Sylvie Pillet 11 Yvon Lebranchu 12 Pascal Turlure 13 Sophie Alain 1, 2
1 EA3175 - Biologie moléculaire et cellulaire des microorganismes
2 Service de Bactériologie, Virologie, Hygiène [CHU Limoges]
3 Laboratoire de Bactériologie-Virologie
4 Service de virologie et d'immunologie biologique
5 Service de Néphrologie-transplantation-dialyse [Bordeaux]
6 Laboratoire de Virologie [Toulouse]
7 Service de Néphrologie - Hypertension Artérielle Dialyse - Transplantation
8 Service de Pharmacologie, toxicologie et pharmacovigilance [CHU Limoges]
9 Service de Néphrologie, Dialyse, Transplantations [CHU Limoges]
10 Laboratoire de Virologie
11 Laboratoire de Virologie
12 Service de néphrologie et immunologie clinique
13 Service d'Hématologie clinique et thérapie cellulaire [CHU Limoges]
Abstract : Objectives Cytomegalovirus (CMV) drug resistance is a therapeutic challenge in the transplant setting. No longitudinal cohort studies of CMV resistance in a real-life setting have been published in the valganciclovir era. We report findings for a French multicentre prospective cohort of 346 patients enrolled at initial diagnosis of CMV infection (clinical trial registered at clinicaltrials.gov: NCT01008540). Patients and methods Patients were monitored for detection of CMV infection for ≥2 years. Real-time detection of resistance by UL97 and UL54 gene sequencing and antiviral phenotyping was performed if viral replication persisted for >21 days of appropriate antiviral treatment. Plasma ganciclovir assays were performed when resistance was suspected. Results Resistance was suspected in 37 (10.7%) patients; 18/37 (5.2% of the cohort) had virological resistance, associated with poorer outcome. Most cases involved single UL97 mutations, but four cases of multidrug resistance were due to UL54 mutations. In solid organ transplant recipients, resistance occurred mainly during primary CMV infection (odds ratio 8.78), but also in two CMV-seropositive kidney recipients. Neither CMV prophylaxis nor antilymphocyte antibody administration was associated with virological resistance. Conclusions These data show the feasibility of surveying resistance. Virological resistance was frequent in patients failing antiviral therapy. More than 1/5 resistant isolates harboured UL54 mutations alone or combined with UL97 mutations, which conferred a high level of resistance and sometimes were responsible for cross-resistance, leading to therapeutic failure.
Type de document :
Article dans une revue
Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2010, epub ahead of print. 〈10.1093/jac/dkq368〉
Liste complète des métadonnées
http://www.hal.inserm.fr/inserm-00533269
Contributeur : Sophie Raherison <>
Soumis le : vendredi 5 novembre 2010 - 15:40:46
Dernière modification le : lundi 10 septembre 2018 - 15:38:56

Lien texte intégral

openaccess

Identifiants

Collections

UNILIM | UMR-S1092 | GEIST | USPC

Citation

Sébastien Hantz, Françoise Garnier-Geoffroy, Marie-Christine Mazeron, Isabelle Garrigue, Pierre Merville, et al.. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study.. Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2010, epub ahead of print. 〈10.1093/jac/dkq368〉. 〈inserm-00533269〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

263

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD